Eplivanserin/volinanserin - Terran Biosciences
Alternative Names: Eplivanserin/volinanserinLatest Information Update: 15 Jan 2024
At a glance
- Originator Terran Biosciences
- Class Antipsychotics; Drug withdrawal therapies; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Neurological disorders; Psychiatric disorders
Most Recent Events
- 19 Dec 2023 Clinical trials in Neurological disorders (unspecified route), prior to December 2023 (Terran Biosciences pipeline, December 2023)
- 19 Dec 2023 Clinical trials in Psychiatric disorders (unspecified route), prior to December 2023 (Terran Biosciences pipeline, December 2023)
- 21 Apr 2022 Eplivanserin licensed to Terran Biosciences worldwide for the treatment of Neurological and Psychiatric disorders (Terran Biosciences pipeline, December 2023)